{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:33:18Z","timestamp":1789907598757,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.reth.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T20:23:21Z","timestamp":1740083001000},"page":"619-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey"],"prefix":"10.1016","volume":"28","author":[{"given":"Fumiko","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Tsurumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reth.2025.02.001_bib2","unstructured":"PMDA Review Reports: Regenerative Medical Products. Available from: https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/0004.html. Accessed on October 27, 2024."},{"key":"10.1016\/j.reth.2025.02.001_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.reth.2025.02.001_bib4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.18609\/cgti.2018.105","article-title":"Management of \u201cout of specification\u201d commercial autologous CAR-T cell products","volume":"4","author":"Bersenev","year":"2018","journal-title":"Cell Gene Ther Insights"},{"issue":"12","key":"10.1016\/j.reth.2025.02.001_bib5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"Suppl 1","key":"10.1016\/j.reth.2025.02.001_bib6","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2021-144897","article-title":"Optimizing commercial manufacturing of tisagenlecleucel for patients in the US: a 4-year experiential journey","volume":"138","author":"Rodrigues","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.reth.2025.02.001_bib7","first-page":"100","article-title":"Commercial manufacturing experience of tisagenlecleucel in Europe: >3 Years Journey","volume":"57","author":"Rodrigues","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.reth.2025.02.001_bib8","unstructured":"ClinicalTrials.Gov [NCT04094311]. Study of Out of Specification for Tisagenlecleucel. Accessed 10 November 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04094311. Accessed on Oct 27, 2024."},{"issue":"2","key":"10.1016\/j.reth.2025.02.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.278","article-title":"Clinical factors associated with failure to manufacture commercial CAR-T cell products among LBCL patients","volume":"30","author":"Patel","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.reth.2025.02.001_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.reth.2025.02.001_bib11","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1080\/10428194.2022.2123232","article-title":"Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel","volume":"63","author":"Fried","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"S1","key":"10.1016\/j.reth.2025.02.001_bib12","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2023-174865","article-title":"Failure and out of specification manufacturing of autologous CAR-T cells could be associated with a high concentration of total nucleated cells, CD3\u00a0+ cells and neutrophils in the apheresis product","volume":"142","author":"Cohet","year":"2023","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.reth.2025.02.001_bib13","doi-asserted-by":"crossref","first-page":"12790","DOI":"10.1182\/blood-2022-168398","article-title":"Early collected leukapheresis material improves tisagenlecleucel manufacturing success and time from order to pickup of the leukapheresis product: a real-world experience","volume":"140","author":"Smrekar","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.reth.2025.02.001_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.18816","article-title":"Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"202","author":"Sharon","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.reth.2025.02.001_bib15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2025.02.001_bib16","series-title":"Japanese society for transplantation and cellular therapy (JSTCT) annual meeting","article-title":"First results of out-of-specification tisagenlecleucel in Japanese patients with R\/R B-all and R\/R DLBCL","author":"Kato","year":"2024"},{"issue":"6","key":"10.1016\/j.reth.2025.02.001_bib17","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s10147-023-02334-w","article-title":"Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan","volume":"28","author":"Goto","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"21","key":"10.1016\/j.reth.2025.02.001_bib18","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukaemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320425000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320425000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T03:29:25Z","timestamp":1741490965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320425000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":17,"alternative-id":["S2352320425000276"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2025.02.001","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine.","name":"copyright","label":"Copyright"}]}}